<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110795">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01708265</url>
  </required_header>
  <id_info>
    <org_study_id>NL39851.041.12.</org_study_id>
    <nct_id>NCT01708265</nct_id>
  </id_info>
  <brief_title>The Dutch Asymptomatic Mitral Regurgitation Trial</brief_title>
  <acronym>Dutch AMR</acronym>
  <official_title>Dutch AMR; Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation; a Multicenter, Randomised Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Interuniversity Cardiology Institute of the Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>WCN, Dutch Network for Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare early mitral valve repair versus a watchful waiting
      strategy in asymptomatic patients with severe organic mitral valve regurgitation and
      preserved left ventricular function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe asymptomatic organic mitral valve (MV) regurgitation with preserved left ventricular
      (LV) function is a challenging clinical entity as data on the recommended treatment strategy
      for these patients are scarce and conflicting, which is reflected in current guidelines.
      European guidelines advocate a more conservative strategy i.e. watchful waiting, with yearly
      echocardiography, whilst American guidelines are more in favour of early surgery to
      reconstruct the MV,  i.e. MV repair (in contrast to MV replacement) in order to prevent
      future LV dysfunction and complaints.

      A number of non-randomised trials show a favourable outcome of early surgery and the early
      surgery strategy has shown to be associated with improved long-term survival, decreased
      cardiac mortality and decreased morbidity compared with the conservative management
      [citations 1-3]. On the other hand, non-randomised trials describe also that a conservative
      strategy (i.e. watchful waiting) can be safely accomplished. If facilitated surgery is
      performed in this population it has proven to be eventually associated with good
      perioperative and postoperative outcome in 50% of the patients at 10 years when careful
      follow-up is being carried out [citation 4]. Non-randomised trials inherently have a number
      of drawbacks. A randomised trial comparing both strategies and objectivising the best
      treatment strategy has never been performed.

      The Dutch AMR (Asymptomatic Mitral Regurgitation) trial is a multicenter, prospective,
      randomised trial comparing early MV repair versus watchful waiting in asymptomatic patients
      with severe organic MV regurgitation and preserved LV function [citation 5].
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite endpoint: cardiovascular mortality, congestive heart failure and hospitalization for nonfatal cardiovascular events</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary outcome is defined as time to first event of the composite endpoint of cardiovascular mortality, congestive heart failure and hospitalization for nonfatal cardiovascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measures the separate component cardiovascular mortality at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Congestive heart failure</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measures the separate component congestive heart failure at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for nonfatal cardiovascular events</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measures the separate component hospitalization for nonfatal cardiovascular events (including but not limited to acute coronary syndrome, arrhythmia and  heart surgery) at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Secondary outcome measures the incidence of all-cause mortality at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs and effectiveness</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures total direct and indirect costs and cost-effectiveness at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures health-related quality of life at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures echocardiographic parameters at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR parameters</measure>
    <time_frame>Min. 5 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures Cardiovascular Magnetic Resonance imaging (CMR)parameters (left ventricular function, left atrial dimensions, pulmonary hypertension) at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures the incidence of asymptomatic atrial fibrillation at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise test parameters</measure>
    <time_frame>Min. 5 years.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures exercise test parameters at a minimum of 5 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Secondary outcome measures brain natriuretic peptide (BNP) plasma levels at a minimum of 5 years.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Surgery complication rate</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The complication rate in the mitral valve surgery group (e.g. re-operation for bleeding, pneumonia, residual or recurrent mitral valve regurgitation) will be determined at a minimum of 5 years.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of surgery</measure>
    <time_frame>Min. 5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Rate of surgery in the watchful waiting group will be determined at a minimum of 5 years.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heart; Disease, Mitral(Valve)</condition>
  <condition>Diseases of Mitral Valve</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Early mitral valve repair</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early mitral valve repair</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Watchful waiting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Watchful waiting</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Watchful waiting</intervention_name>
    <description>In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.</description>
    <arm_group_label>Watchful waiting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early mitral valve repair</intervention_name>
    <description>Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.</description>
    <arm_group_label>Early mitral valve repair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic

          -  Severe organic mitral valve regurgitation.

          -  Preserved left ventricular function (left ventricular ejection fraction &gt;60% and left
             ventricular end-systolic dimension ≤45 mm)

          -  The likelihood of MV repair should be more than 90% determined by the local heart
             team with a cardiologist and cardiothoracic surgeon

        Exclusion Criteria:

          -  Pulmonary hypertension (&gt;50 mmHg at rest)

          -  Atrial fibrillation

          -  Physical inability as determined by the heart team to undergo surgery

          -  Other life-threatening morbidity

          -  Higher expected surgical risks in advance, according to the dedicated heart team

          -  Moderate to severe kidney disease (eGFR less than 30 mL/min)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven AJ Chamuleau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Utrecht (UMC Utrecht)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jolanda Kluin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Utrecht (UMC Utrecht)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert JM Klautz, Prof. MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center (LUMC Leiden)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven AJ Chamuleau, MD, PhD</last_name>
    <phone>0031 88 75 56176</phone>
    <email>S.A.J.Chamuleau@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jolanda Kluin, MD, PhD</last_name>
    <phone>0031 88 75 56179</phone>
    <email>J.Kluin@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert JM Klautz, prof. MD PhD</last_name>
      <phone>0031 71 526 4022</phone>
      <email>r.j.m.klautz@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Robert JM Klautz, prof. MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosemarijn Jansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMC Utrecht)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven AJ Chamuleau, MD, PhD</last_name>
      <phone>0031 88 75 56176</phone>
      <email>S.A.J.Chamuleau@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jolanda Kluin, MD, PhD</last_name>
      <phone>0031 88 75 56179</phone>
      <email>J.Kluin@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Steven AJ Chamuleau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jolanda Kluin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosemarijn Jansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://dutchamr.nl/</url>
    <description>Dutch AMR study homepage</description>
  </link>
  <reference>
    <citation>Ling LH, Enriquez-Sarano M, Seward JB, Orszulak TA, Schaff HV, Bailey KR, Tajik AJ, Frye RL. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation. 1997 Sep 16;96(6):1819-25.</citation>
    <PMID>9323067</PMID>
  </reference>
  <reference>
    <citation>Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, Scott C, Schaff HV, Tajik AJ. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. 2005 Mar 3;352(9):875-83.</citation>
    <PMID>15745978</PMID>
  </reference>
  <reference>
    <citation>Chenot F, Montant P, Vancraeynest D, Pasquet A, Gerber B, Noirhomme PH, El Khoury G, Vanoverschelde JL. Long-term clinical outcome of mitral valve repair in asymptomatic severe mitral regurgitation. Eur J Cardiothorac Surg. 2009 Sep;36(3):539-45. Epub 2009 Jul 25.</citation>
    <PMID>19632855</PMID>
  </reference>
  <reference>
    <citation>Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, Schemper M, Maurer G, Baumgartner H. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. 2006 May 9;113(18):2238-44. Epub 2006 May 1.</citation>
    <PMID>16651470</PMID>
  </reference>
  <reference>
    <citation>Tietge WJ, de Heer LM, van Hessen MW, Jansen R, Bots ML, van Gilst W, Schalij M, Klautz RJ, Van den Brink RB, Van Herwerden LA, Doevendans PA, Chamuleau SA, Kluin J. Early mitral valve repair versus watchful waiting in patients with severe asymptomatic organic mitral regurgitation; rationale and design of the Dutch AMR trial, a multicenter, randomised trial. Neth Heart J. 2012 Mar;20(3):94-101. doi: 10.1007/s12471-012-0249-y.</citation>
    <PMID>22354529</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 5, 2013</lastchanged_date>
  <firstreceived_date>October 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>S.A.J. Chamuleau</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Asymptomatic Mitral Valve Regurgitation</keyword>
  <keyword>Asymptomatic Mitral Valve Insufficiency</keyword>
  <keyword>Mitral Valve Repair</keyword>
  <keyword>Watchful Waiting</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
